OBI Pharma and AP Biosciences sign technology collaboration agreement to develop next-generation ADC

CAR-T Digest - August 2020

3 September 2025: OBI Pharma and AP Biosciences sign technology collaboration agreement to develop next-generation ADC

OBI Pharma entered into a Material Transfer and Technology Development Agreement with AP Biosciences to collaborate on developing a next-generation bispecific ADC
AP Biosciences will supply the bispecific antibody, while OBI Pharma will apply its GlycOBI conjugation, EndoSymeOBI enzyme, and HYPrOBI linker technologies to create the ADC
The completed bispecific ADC will be returned to AP Biosciences for evaluation of development potential and possible future licensing
OBI Pharma highlighted the collaboration as a strategic effort combining both companies’ strengths to advance bispecific ADC innovation
The partnership underscores Taiwan’s biotech progress in ADCs and aims to deliver new treatment options for patients